"Pitch Me an M&A Deal": How to Answer in Interviews

Introduction

A stock pitch and a deal pitch sound like the same question in different clothes, but they test different instincts. A stock pitch asks whether a share price is wrong. A deal pitch asks whether two companies are worth more together than apart, and what one should pay for the other.

That second question is the daily work of an M&A or coverage banker, who walks into a client meeting with an idea, a price and a way to fund it. So the interviewer is listening for commercial logic: a buyer with a real problem, a target that solves it better than building would, and arithmetic that survives a premium, a financing plan and a regulator. Most candidates stop at the strategy story; the strongest add the price, the payment and the risks: what it costs, how it gets paid for and what could stop it.

This guide covers what interviewers grade, an eight-part structure, a worked pitch built from public filings (Church & Dwight acquiring Prestige Consumer Healthcare, strictly as an interview illustration), short and long versions, the follow-ups, and how to prepare your own.

Both questions end in a recommendation you defend under follow-ups, and the similarity stops there. One casts you as an investor betting against the market; the other as an adviser to the buyer who has to convince a board.

The last row is the one candidates forget: a stock pitch can be right while nobody acts, but a deal pitch only works if the target's board accepts it and regulators allow it.

The Question and Its Variants

The prompt comes in several forms, and the form tells you where to start:

The last one is the sell-side version: start from the target and find the natural buyer, usually the one with the largest synergies, the cheapest currency or the most pressing need, because that buyer can pay the most. The structure below works in both directions.

M&A Pitch

A short, structured argument that one company should acquire another, covering the strategic rationale, an indicative price, how the buyer would pay, the main risks and the timing. Bankers build these ideas for corporate clients; in an interview, "pitch me a deal" asks for one out loud in one to three minutes.

The Five Things on the Scorecard

Interviewers rarely spell it out, but the answer is scored on the dimensions a managing director uses to decide whether an idea deserves a client meeting:

The Eight Building Blocks

Each part depends on the one before: synergies set what the buyer can afford, the price sets how it must pay, and the payment drives the accretion and leverage math.

Where the Judgment Sits

Steps one, two and eight are storytelling; three to six are where the story meets numbers. The difference between cost and revenue synergies decides how much of a synergy estimate deserves credit. The premium is measured from the unaffected share price before any rumor; public-company premiums have tended to sit between 20% and 40%, and the mechanics of measuring a control premium matter whenever a target's stock has already moved.

Build the valuation instincts behind a deal pitch: The 160-page PDF covers merger math, multiples and the M&A follow-ups interviewers use to pressure-test an idea, access the IB Interview Guide and walk into your superday with the frameworks in one place.

Here is the structure applied to two real US consumer companies, with figures from their public filings rounded the way a candidate would say them.

The Buyer and Its Problem

Church & Dwight owns Arm & Hammer, OxiClean, TheraBreath, Hero acne patches, Zicam and Waterpik, and had about $6.2 billion of sales in 2025. At a February 2026 investor conference it restated its acquisition criteria: mainly #1 or #2 brands, high growth, high margins, fast-moving consumables, asset light, and a fit with its own manufacturing, logistics and purchasing. Its problem has three parts:

Meanwhile the balance sheet is underused. Total debt was about 1.6x bank EBITDA of roughly $1.5 billion at the end of 2025, net debt was about $2 billion at mid-2026 according to its second-quarter 2026 results, and management has put its acquisition capacity at about $5.5 billion. The equity is worth over $20 billion, in the mid-20s times expected 2026 earnings.

Why Prestige Fits, and Where It Does Not

Prestige Consumer Healthcare sells over-the-counter brands such as Dramamine, Clear Eyes, Chloraseptic and Compound W, and added Breathe Right nasal strips in June 2026. In the fiscal year to March 2026 it earned adjusted EBITDA of about $354 million on revenue of about $1.1 billion, a margin above 32%.

The weak row is the one an interviewer will attack, so raise it first. Most of the decline came from a supply shortfall at third-party makers of Clear Eyes rather than from collapsing demand, and Church & Dwight's supply chain and record with acquired brands (Hero and TheraBreath both grew double digits in 2025) are the case for fixing it and restoring portfolio growth.

Valuation and the Offer Price

Prestige's shares sold off after its fiscal 2026 results and trade in the mid-to-high $40s, against a February 2026 high of about $71. With about 47.5 million shares and roughly $2 billion of net debt after Breathe Right, the enterprise value is a little over $4 billion. Adding Breathe Right (about $95 million of EBITDA) and the smaller LaCorium deal (an expected $12 million) to the fiscal 2026 figure gives pro forma EBITDA of roughly $460 million.

The premium sits at the top of the usual range on purpose: the board will judge any offer against the past year's high, and $63 is still below it. The implied 11x EBITDA matches what Prestige paid for Breathe Right, according to its March 2026 announcement, and sits under the 12x Church & Dwight used to illustrate its own capacity.

Financing and Accretion

The total bill is about $5 billion: roughly $3 billion for the equity plus about $2 billion of Prestige debt to refinance or assume.

All cash takes pro forma leverage to the mid-3s, near the limit of the company's own capacity math, with committed bridge financing at signing. Paying a quarter in stock adds about 3% to the share count but keeps leverage nearer 3x.

Pro Forma Leverage

Net debt divided by EBITDA, recalculated as if an acquisition had already closed: the buyer's existing debt plus acquisition debt and any assumed target debt, over combined EBITDA. Lenders and rating agencies watch it because it shows how stretched the balance sheet is on day one and how long deleveraging will take.

The fastest accretion check compares earnings yields. On guided fiscal 2027 EPS of about $4.60, Prestige earns roughly 7% on a $63 price, while new debt at an assumed 5% costs under 4% after tax and Church & Dwight stock at about 25x earnings costs about 4%. Both currencies are cheaper than what they buy, so EPS accretion follows either way: about $220 million of Prestige net income, less about $110 million of after-tax interest on $3 billion of new debt, adds about $110 million to a base near $900 million. The full accretion and dilution walk-through adds the share count, integration costs and synergy phasing.

Earnings Yield

Net income divided by equity value, or the inverse of the P/E ratio: a stock at 20x earnings has a 5% earnings yield. In merger analysis it is a quick accretion test, because paying with a currency that costs less than the target's earnings yield at the offer price usually lifts EPS before synergies.

Synergies, Risks and Why Now

Assume cost synergies of about 5% of Prestige's roughly $1.3 billion of sales, about $65 million, from procurement and contract-manufacturing scale, logistics and duplicated public-company costs; headcount savings are small at a company of about 890 employees. The test is whether those savings pay for the premium: capitalized at the deal's 11x, they are worth roughly $700 million before integration costs, against a premium of about $850 million. The gap rests on a Clear Eyes recovery and on discounted revenue upside from Church & Dwight's international push.

The risks and the timing, in short:

The 60-Second Version

Compress the eight blocks into about 150 words: the buyer's problem before the target, the price before the risks, every number rounded.

What sticks is the shape: one sentence per block, numbers the interviewer can check, and the honest risk saved for last.

The 3-Minute Version

In a superday, or when the interviewer says to take your time, keep the same order and spend the extra two minutes on evidence rather than adjectives:

Why Would the Target Sell?

A public board sells when an offer beats the standalone plan, not because a buyer is interested. Prestige's plan is to cut leverage from about 4x after Breathe Right to under 3x by fiscal 2028 while growing organically by low single digits. The answer: a 40% premium delivers at closing a value the plan might take years to reach. Then concede that holders who bought near the high will push for more, and say where your walk-away price sits.

What Would Antitrust Say?

Start with process: a $5 billion deal is far above the 2026 Hart-Scott-Rodino threshold of $133.9 million, so both sides file and wait 30 days (15 for a cash tender offer), longer with a second request, under the FTC's premerger review process. Then substance, with markets defined as narrowly as a regulator would:

If one of those narrow product markets proves concentrated, the usual fix is selling a brand; the remedies and second requests that shape deal timelines are worth knowing before you call any deal clean.

Is It Accretive, and Does That Matter?

Yes, and that is the trap. With after-tax debt under 4%, almost any target bought below the mid-20s on P/E is accretive in a cash deal, so accretion is evidence of cheap financing, not of value creation. The better test is return on invested capital: pro forma EBITDA less modest depreciation and about 25% tax is roughly $320 million of after-tax operating profit on a $5 billion price, a little over 6% in year one and above 7% with the cost synergies.

What If the Buyer's Stock Falls?

In an all-cash deal, Prestige holders get the same price whatever Church & Dwight shares do; a fall is just the market's verdict on the price. With stock in the mix, a fixed exchange ratio passes the fall to Prestige holders, a fixed-value structure makes the buyer issue more shares, and a collar applies one rule inside a price band and the other beyond it, trade-offs covered in how buyers choose between stock and cash consideration.

Deal pitches live or die on the follow-ups: Practice M&A, valuation and accretion questions with worked answers, start practicing interview questions for free and get comfortable defending a price under pressure.

Two or three pitches cover almost every interview if each has a different deal shape: a cash bolt-on like the example, a stock-for-stock combination of two larger companies, and one in the sector of the group you are meeting. Different shapes give you different financing and antitrust stories. For each, pull the same list from the latest 10-K, 10-Q, earnings release and investor presentation:

The market numbers need refreshing the morning of the interview, and a quick news search should confirm the pairing has not been announced or reported.

Weak pitches fail in predictable ways:

The question sounds open-ended, but the answer has a shape. A buyer with a real problem, a target that solves it, a premium the synergies can largely justify, a financing plan the balance sheet can carry, and risks you name before the interviewer does: that is the whole pitch, whether it lasts sixty seconds or three minutes.

The worked example is a reminder that a strong pitch does not need to predict the future. Neither company may ever consider the idea. What the interviewer is buying is the method: filings read, numbers rounded, the weak criterion admitted, the walk-away price set.

Build two or three pitches that way, rehearse both lengths out loud, and expect the follow-ups to go straight to price, financing and antitrust. If your answers there are as prepared as your opening, the question becomes one of the easiest wins in the interview.